Literature DB >> 23359689

Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.

Jean-Philippe Defour1, Miki Itaya, Vitalina Gryshkova, Ian C Brett, Christian Pecquet, Takeshi Sato, Steven O Smith, Stefan N Constantinescu.   

Abstract

Dimerization of single-pass membrane receptors is essential for activation. In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQFP motif separates the transmembrane (TM) and intracellular domains. Using a combination of mutagenesis, spectroscopy, and biochemical assays, we show that W515 of this motif impairs dimerization of the upstream TpoR TM helix. TpoR is unusual in that a specific residue is required for this inhibitory function, which prevents receptor self-activation. Mutations as diverse as W515K and W515L cause oncogenic activation of TpoR and lead to human myeloproliferative neoplasms. Two lines of evidence support a general mechanism in which W515 at the intracellular juxtamembrane boundary inhibits dimerization of the TpoR TM helix by increasing the helix tilt angle relative to the membrane bilayer normal, which prevents the formation of stabilizing TM dimer contacts. First, measurements using polarized infrared spectroscopy show that the isolated TM domain of the active W515K mutant has a helix tilt angle closer to the bilayer normal than that of the wild-type receptor. Second, we identify second-site R514W and Q516W mutations that reverse dimerization and tilt angle changes induced by the W515K and W515L mutations. The second-site mutations prevent constitutive activation of TpoR W515K/L, while preserving ligand-induced signaling. The ability of tryptophan to influence the angle and dimerization of the TM helix in wild-type TpoR and in the second-site revertants is likely associated with its strong preference to be buried in the headgroup region of membrane bilayers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359689      PMCID: PMC3574938          DOI: 10.1073/pnas.1211560110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper.

Authors:  Weiming Ruan; Verena Becker; Ursula Klingmüller; Dieter Langosch
Journal:  J Biol Chem       Date:  2003-11-05       Impact factor: 5.157

2.  A novel MPL point mutation resulting in thrombopoietin-independent activation.

Authors:  M Abe; K Suzuki; O Inagaki; S Sassa; H Shikama
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

3.  Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer.

Authors:  M Onishi; A L Mui; Y Morikawa; L Cho; S Kinoshita; G P Nolan; D M Gorman; A Miyajima; T Kitamura
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

Review 4.  Experimentally determined hydrophobicity scale for proteins at membrane interfaces.

Authors:  W C Wimley; S H White
Journal:  Nat Struct Biol       Date:  1996-10

5.  Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor.

Authors:  K F Kubatzky; W Ruan; R Gurezka; J Cohen; R Ketteler; S S Watowich; D Neumann; D Langosch; U Klingmüller
Journal:  Curr Biol       Date:  2001-01-23       Impact factor: 10.834

6.  Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain.

Authors:  S N Constantinescu; T Keren; M Socolovsky; H Nam ; Y I Henis; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

7.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

Authors:  F Kohlhuber; N C Rogers; D Watling; J Feng; D Guschin; J Briscoe; B A Witthuhn; S V Kotenko; S Pestka; G R Stark; J N Ihle; I M Kerr
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

8.  Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.

Authors:  Jianmin Ding; Hirokazu Komatsu; Atsushi Wakita; Miyuki Kato-Uranishi; Masato Ito; Atsushi Satoh; Kazuya Tsuboi; Masakazu Nitta; Hiroshi Miyazaki; Shinsuke Iida; Ryuzo Ueda
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

9.  The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.

Authors:  J G Drachman; J D Griffin; K Kaushansky
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

10.  Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.

Authors:  F J de Sauvage; K Carver-Moore; S M Luoh; A Ryan; M Dowd; D L Eaton; M W Moore
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  22 in total

1.  Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation.

Authors:  Thorben M Hummel; Theresa Ackfeld; Marco Schönberg; Gregor Ciupka; Falk Schulz; Anne Oberdoerster; Joachim Grötzinger; Jürgen Scheller; Doreen M Floss
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

Review 2.  Juxtamembrane contribution to transmembrane signaling.

Authors:  Wei Deng; Renhao Li
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

3.  An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Authors:  J-P Defour; Y Hoade; A-M Reuther; A Callaway; D Ward; F Chen; S N Constantinescu; N C P Cross
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

4.  Evolutionary-guided de novo structure prediction of self-associated transmembrane helical proteins with near-atomic accuracy.

Authors:  Y Wang; P Barth
Journal:  Nat Commun       Date:  2015-05-21       Impact factor: 14.919

5.  Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.

Authors:  Stephan Wilmes; Maximillian Hafer; Joni Vuorio; Julie A Tucker; Hauke Winkelmann; Sara Löchte; Tess A Stanly; Katiuska D Pulgar Prieto; Chetan Poojari; Vivek Sharma; Christian P Richter; Rainer Kurre; Stevan R Hubbard; K Christopher Garcia; Ignacio Moraga; Ilpo Vattulainen; Ian S Hitchcock; Jacob Piehler
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

Review 6.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

7.  Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.

Authors:  J-P Defour; I Chachoua; C Pecquet; S N Constantinescu
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

8.  Dynamic analysis of GH receptor conformational changes by split luciferase complementation.

Authors:  Ying Liu; Philip A Berry; Yue Zhang; Jing Jiang; Peter E Lobie; Ramasamy Paulmurugan; John F Langenheim; Wen Y Chen; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2014-09-04

Review 9.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

10.  Erythropoiesis from human embryonic stem cells through erythropoietin-independent AKT signaling.

Authors:  William S Kim; Yuhua Zhu; Qiming Deng; Chee Jia Chin; Chong Bin He; Amanda J Grieco; Gautam G Dravid; Chintan Parekh; Roger P Hollis; Timothy F Lane; Eric E Bouhassira; Donald B Kohn; Gay M Crooks
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.